Sp1201
EMERGING SCREENING TESTS FOR LIVER CANCER SCREENING--ABBREVIATED MRI, BLOOD BASED ASSAYS, NEW PROTEIN BIOMARKER PANELS, ETC
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
Talks on the blood based screening test clinical trial results that will occur in 2022 and 2023 (ECLIPSE, PREEMPT, BLUE-C) and effects on clinical care; updates on multi-cancer early detection test; emerging screening tests (Oncoguard, Colonosight, etc). This session will provide expert guidance on the tests and their appropriate use in clinical care. LIVE STREAM SESSION
Talks on the blood based screening test clinical trial results that will occur in 2022 and 2023 (ECLIPSE, PREEMPT, BLUE-C) and effects on clinical care; updates on multi-cancer early detection test; emerging screening tests (Oncoguard, Colonosight, etc). This session will provide expert guidance on the tests and their appropriate use in clinical care. LIVE STREAM SESSION
Presenter
University of Michigan
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
INTRODUCTION
SOCIETY: AGA
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
